Lat­est news: Com­mit­tee votes to restart J&J vac­ci­na­tions, check­point gi­ants prep de­fense, un­der­dog vac­cine en­ters the spot­light, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If this re­port was help­ful in re­cap­ping it all for you, please do share it with your col­leagues.

Re­sume J&J vac­ci­na­tions, com­mit­tee votes

The ver­dict is in: A CDC ad­vi­so­ry com­mit­tee vot­ed late Fri­day to restart vac­ci­na­tions with J&J’s Covid-19 vac­cine, which is on a hia­tus fol­low­ing re­ports of rare but po­ten­tial­ly life-threat­en­ing blood clots. They stopped short of re­strict­ing its use to spe­cif­ic pop­u­la­tions or spec­i­fy­ing a new warn­ing; how­ev­er, J&J not­ed ahead of the vote that it has agreed to add a warn­ing to the la­bel re­gard­ing the risks, which they said is con­cen­trat­ed in fe­males ages 18 through 49 years and pos­si­bly linked to its vac­cine. In to­tal, the CDC said it has now spot­ted 15 cas­es of the blood clots with low platelets — with more un­der in­ves­ti­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER